Curza is a biotechnology company focused on developing novel antibiotics to combat the growing threat of antibiotic resistance and biofilm-related infections. The company operates in the pharmaceutical and healthcare markets, primarily serving medical institutions, healthcare providers, and patients affected by drug-resistant bacterial infections. Curza's business model revolves around research and development of new antibiotic classes, particularly targeting ESKAPE pathogens, which are known for their resistance to current treatments. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary antibiotics. Curza's lead program, CZ 02, is a broad-spectrum antibiotic aimed at drug-resistant Gram-negative bacteria, showcasing the company's commitment to addressing critical healthcare challenges.

Keywords: antibiotic resistance, biofilm infections, ESKAPE pathogens, Gram-negative bacteria, pharmaceutical R&D, healthcare innovation, biotechnology, drug development, medical institutions, healthcare providers.